Advancements in ADCs Using SMARTag® Technology
Summary: Catalent’s SMARTag® technology platform offers ADC and biologics developers a one-step toolkit to develop optimized ADCs and bioconjugates. The SMARTag® technology enables site-specific, controlled drug-protein conjugation, and uses only naturally occurring modifications to proteins requiring minimal cell-line engineering.
Hear Penelope Drake, Director of R&D for Catalent Biologics, present on the demonstrated success of SMARTag® across several therapeutic modalities in this on-demand webinar.